News | PET Imaging | July 16, 2021

Swiss Nuclear Medical Imaging Company Gets Financial Boost

Positrigo receives funding from the European Innovation Council (EIC Fund) for its breakthrough brain PET scanner technology

Positrigo founders Max Ahnen, Ph.D. (left) and Jannis Fischer, Ph.D.

July 16, 2021 — Positrigo, a company developing nuclear medical imaging devices to advance functional imaging, today announced that the European Innovation Council Fund (EIC Fund) awarded the company during this year’s funding cycle with EUR 1.5 million to top up the second tranche of Positrigo’s series A and committed to invest additionally up to EUR 3.5 million in a future financing round. After receiving the prestigious EIC Accelerator grant last year, this additional funding is testament for Positrigo’s breakthrough technology and is exclusively granted to high impact and deep tech start-up companies.

Positrigo is an ETH Zurich start-up, developing ultra-compact Positron Emission Tomography (PET) systems. The company focuses on delivering versatile head PET systems with applications in early dementia diagnosis and other brain related disorders.

“Positrigo’s cutting-edge technology and its market potential will allow to meet the increasing demand for PET examinations in the coming years and make brain scanning widely affordable. I am glad the EIC Fund invests into this skillful team of innovative entrepreneurs to commercialize the technology and scale up the company of brain PET scanners for an accessible early discovery of Alzheimer’s disease,” said Heidi Kakko, EIC Fund Investment Committee member.

Jannis Fischer, Ph.D., CEO and co-founder of Positrigo stated: “We are honored and pleased about the trust and continued support we receive from the EIC. This additional funding will allow us to accelerate our efforts to commercialize NeuroLF, a small and compact brain PET scanner, to enable clinicians the early detection of Alzheimer’s disease.”

Earlier this year the company finished the first in-vivo clinical trial to demonstrate that their innovative brain PET scanner performed successfully in a highly constrained environment. This accomplishment was possible thanks to the collaboration of interdisciplinary teams at University Hospital Zurich and the ETH Zurich. “We are grateful to have such great clinical and academic partners which support us to develop cutting-edge technology”, concluded Max Ahnen, Ph.D., COO and co-founder of Positrigo. “The recognition by EIC motivates us even more to foster these collaborations with the goal to advance the nuclear medical imaging field.”

For more information: www.positrigo.com

 

Related Alzheimers' content:

VIDEO: Researchers Use MRI to Predict Alzheimer's Disease

Brain Iron Accumulation Linked to Cognitive Decline in Alzheimer's Patients

Good Results for Alzheimer’s Imaging Agent

NIH Augments Large Scale Study of Alzheimer’s Disease Biomarkers

Alzheimer’s Association Launches New Website for IDEAS Study

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

New Super-resolution Technique Allows for More Detailed Brain Imaging

 

Related Content

HealthMyne, a pioneer in applied radiomics, announced today that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy.

Semi-automatic lesion identification: (A) Manual ROI indication. In blue, it is possible to observe the axes that cross the lesion manually delineated by the radiologist on a plane of the MPR. The intensity of the lesion boundary (estimated) is represented with a red outline. (B) Additional axes can be dragged onto other orthogonal MPR views. From left to right, it is possible to observe the initial long axis outlined by the radiologist and the 2D contours on the axial, coronal and sagittal views of the lesion used as a starting point for the RPM algorithms. (C) Resulting 3D contour of the lesion (in blue).

News | Radiomics | September 21, 2021
September 21, 2021 —  HealthMyne, a pioneer in applied radiomics, announced today that peer-reviewed ...
An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging.

An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging. Illustration by Arjun Valiya Parambathu

News | Magnetic Resonance Imaging (MRI) | September 20, 2021
September 20, 2021 — ...
News | Breast Imaging | September 20, 2021
September 20, 2021 — ImageCare Centers is unveiling its new “PINK Better Mammo” service with the addition of...
IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Shimadzu Medical Systems USA, a leading manufacturer of advanced medical X-ray imaging systems, has announced that the Trinias unity edition product line has been awarded a contract from Vizient, Inc., a healthcare performance improvement company, effective Sept. 1, 2021.
News | X-Ray | September 17, 2021
September 17, 2021 — Shimadzu Medical Systems USA, a leading manufacturer of advanced medical...
Avoiding contrast dyes for imaging tests not necessary if concerned about iodine allergy, peer-reviewed study concludes #MRI

Getty Images

News | Contrast Media Injectors | September 16, 2021
September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthc
Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond
Feature | Nuclear Imaging | September 16, 2021 | By Staff of the American Society of Nuclear Cardiology (ASNC)
A year after COVID-19 turned the world upside do
This is an example of 3-D ultrasound imaging on a breast, designed to help increase efficiency and diagnostic accuracy in any practice. Image courtesy of Hologic.

This is an example of TriVu ultrasound imaging on a breast, designed to help increase efficiency and diagnostic accuracy in any practice. Image courtesy of Hologic.

Feature | Breast Imaging | September 15, 2021 | By Jennifer Meade
The...